(1)
LUND, Sweden, Dec. 11, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia"), a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray for the early detection of cancer, today announced that the company will be hosting the third webinar in the series on IMMray PanCan-d, Immunovia's test for early detection of pancreatic cancer. This third webinar will cover IMMray
PanCan-d verification study results and its clinical use including feedback from experts in pancreatic cancer and pancreatic diseases.
Event Details: Webinar No. 3: Immunovia's IMMray PanCan-d Webinar Series Verification Study and Clinical Use
Date and Time: December 17, 2020 at 15:00 CET
Moderator for the Webinar is CEO Patrik Dahlen